Skip to content

News items:


  • Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

    Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

    The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy. LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) — GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it… Read…

    Read full news article


  • Cyclomics appoints advisory board

    Cyclomics appoints advisory board

    Cyclomics is pleased to announce that it has established its advisory board to help the company to shape its strategy for continued growth and development. The advisory board is chaired by Joris Schuurmans, a seasoned executive with long-standing experience in molecular cancer diagnostics, currently serving as Chief Development Officer at SkylineDx, and is furthermore comprised… Read…

    Read full news article


  • Cyclomics co-founder Dr. Jeroen de Ridder publishes paper in Nature

    Cyclomics co-founder Dr. Jeroen de Ridder publishes paper in Nature

    The research group of Jeroen de Ridder, co-founder of Cyclomics and inventor of CyclomicsSeq technology, has published a research article in Nature. The work describes an elegant use of Oxford Nanopore sequencing to classify paediatric brain tumor by means of real-time analysis of methylation hallmarks. This novel approach enables surgeons to obtain a superfast diagnosis… Read…

    Read full news article


  • The Dutch Cancer Foundation (KWF) granted 1.25M to OralScreen to tackle the diagnostics challenges of oral-cavity cancers.

    The Dutch Cancer Foundation (KWF) granted 1.25M to OralScreen to tackle the diagnostics challenges of oral-cavity cancers.

    In collaboration with KWF, NWO, and Amsterdam UMC,  Cyclomics participates in the OralScreen consortium led by Dr. J.B. Poell from the VUMC. OralScreen has the ambition of revolutionizing early cancer detection in the oral cavity. Oral cavity cancers are often detected in a late stage, when the survival chances are severely reduced, affecting the quality… Read…

    Read full news article


  • Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer

    Oxford Nanopore Technologies and Cyclomics begin developer  testing on non-invasive method for accurate and fast detection of molecules associated with cancer

    Research collaboration has resulted in new ‘liquid biopsy’ research workflowusing nanopore sequencing to detect molecules that are associated with cancer,circulating in blood. Thursday 16th March Oxford Nanopore Technologies and Dutch start-up Cyclomics today announced the ‘developeraccess’ of a new research workflow that combines the world’s first nanopore sequencing-basedsolution for ultra-sensitive detection of circulating tumour DNA… Read…

    Read full news article


  • Cyclomics announces completion of seed financing round

    Cyclomics announces completion of seed financing round

    To accelerate the development of innovate technologies in the field of cancer genetic testing, Cyclomics has completed a financing round driven by a group of private investors. In recent years, the primary focus of Cyclomics has been on the development of its core CyclomicsSeq technology, which has found its way in multiple collaborative research projects… Read…

    Read full news article


  • Appointment of Rodrigo Meneses as Bioinformatics Scientist at Cyclomics

    Appointment of Rodrigo Meneses as Bioinformatics Scientist at Cyclomics

    We are happy to announce the expansion of our bioinformatics team with the addition of Rodrigo Meneses. Rodrigo has a Masters degree in Bioinformatics from Ghent University and a strong biological background due to his degree from the University of Aveiro. His experience within a medical setting is a great addition to the team and… Read…

    Read full news article


  • Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.

    Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.

    We are happy to announce our newest team member to join Cyclomics. With a background in Biology, Rita Ferreira holds a PhD degree in Medical Microbiology (2022) from the University of Groningen. Rita’s expertise in cell and molecular biology will contribute to the design and implementation of novel molecular assays and the overall development of… Read…

    Read full news article


  • Cyclomics finalizes Oncode clinical proof-of-concept project

    Cyclomics finalizes Oncode clinical proof-of-concept project

    Our technology, CyclomicsSeq, has been used in a recent Clinical Proof-of-Concept(Cpoc) project funded by the Oncode Institute. In this project several patients with advanced head and neck cancer were monitored over several months to obtain information about responders and non-responders for the given treatment. The project was performed in collaboration with the Netherlands Cancer Institute… Read…

    Read full news article


  • Cyclomics presents technology at Oxford Nanopore Cancer Research Symposium

    Cyclomics presents technology at Oxford Nanopore Cancer Research Symposium

    Cyclomics’ CSO Wigard Kloosterman presented the CyclomicsSeq technology at the online Cancer Research Symposium organised by Oxford Nanopore Technologies. The recording of the presentation is now available online. The presentation covers details of the CyclomicsSeq technology, which enables consensus sequencing of DNA fragments using the Oxford Nanopore sequencing instruments. Cyclomics aims at delivering flexible, accurate… Read…

    Read full news article


  • Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

    The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy. LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) — GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it… Read…

Older posts: